Evidence map›Paper›PMID 40266922›Full record

ArticleVeterinary sciences2025

Development of a New Indirect ELISA Test for the Detection of Anti-Feline Coronavirus Antibodies in Cats.

Irene Ferrero, Sarah Dewilde, Paolo Poletti, Barbara Canepa, Enrica Giachino, Paola Dall'Ara, Joel Filipe

Abstract read
In one paragraph

Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Irene FerreroAgrolabo S.p.A., 10010 Scarmagno, Italy.
Sarah DewildeGem Forlab S.r.l., 10014 Caluso, Italy.
Paolo PolettiAgrolabo S.p.A., 10010 Scarmagno, Italy.
Barbara CanepaGem Forlab S.r.l., 10014 Caluso, Italy.
Enrica GiachinoAgrolabo S.p.A., 10010 Scarmagno, Italy.
Paola Dall'AraDepartment of Veterinary Medicine and Animal Sciences, University of Milan, 26900 Lodi, Italy.ORCID 0000-0002-8542-9476
Joel FilipeDepartment of Veterinary Medicine and Animal Sciences, University of Milan, 26900 Lodi, Italy.ORCID 0000-0001-8849-2051

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesFeline coronavirus (FCoV) belongs to the family Coronaviridae and includes two pathotypes, the less virulent feline enteric coronavirus (FECV), which replicates in the enteric epithelial cells, and feline infectious peritonitis virus (FIPV), which is more virulent, replicates efficiently within monocytes/macrophages with systemic involvement and may cause feline infectious peritonitis (FIP), a progressive and often fatal disease. The diagnosis of FIP is complex and requires different examinations. Among serological tests, the indirect immunofluorescent antibody test (IFAT), considered the gold standard, and the enzyme-linked immunosorbent assay (ELISA) are the most widely used to detect FCoV antibodies. The aim of this work was the development of FCoVCHECK Ab ELISA, a new rapid indirect test for the detection of FCoV antibodies in feline serum/plasma samples.

methodsFCoVCHECK Ab ELISA was developed after a meticulous set-up and cut-off analysis through several methods, including the Youden's index and ROC curve, to achieve the best test performance. It was validated by testing 110 feline sera (62 positives and 48 negatives) against the reference IFAT and compared with two other rapid ELISA tests, INgezim Corona Felino (Gold Standard Diagnostics) and ImmunoComb Feline Coronavirus (FCoV) [FIP] Antibody Test Kit (Biogal).

conclusionsFCoVCHECK Ab ELISA agreed with IFAT at 96.4% (93.5% sensitivity, 95% confidence interval (CI): 83.5-97.9%; 100% specificity, 95% CI: 90.8-100%), with ImmunoComb FCoV at 93.6% and with INgezim Corona Felino at 82.7%. Intra- and inter-assay accuracy and precision gave coefficients of variation lower than 20%. Compared to IFAT, the new assay correctly identifies positive and negative samples with a good correlation, and, in addition, it is simpler, faster and provides a less subjective reading of the results.

Indexed as

CoronavirusELISAFCoVFCoVCHECKFECVFIPFIPVIFAT

Identifiers

PMID40266922
PMCPMC11946180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.